Plasmapheresis. Technical aspects and indications.
In summary, use of plasmapheresis has changed in recent years given advances in medical technology that have allowed a wider clinical application in the critical care setting. Membrane filtration technology has provided an alternative to centrifugation that can be easily applied in intensive care units. Use of plasmapheresis has also changed in recent years reflecting the availability of evidence largely obtained from controlled prospective studies. However, the clinical efficacy of plasmapheresis for many acute renal conditions is still controversial. Plasmapheresis appears to be a useful adjunct to conventional therapy in the treatment of anti-GBM nephritis, severe dialysis-dependent forms of pauciimmune RPGN, cryoglobulinemia, and HUS-TTP. Reported data also suggest a possible benefit of plasmapheresis in patients with myeloma cast nephropathy, sepsis, and poisoning/overdose, but the case for plasmapheresis in these disorders is largely unproven and the reported evidence insufficient to recommend its use outside research settings. In contrast, data from controlled trials do not support a role for plasmapheresis in immune complex-mediated RPGN, such as lupus nephritis, and acute allograft rejection. The more widespread application of prospective, randomized, controlled clinical trials should help to better define the value of plasmapheresis for treatment of acute renal diseases.
Madore
François
F
Renal Division, Department of Medicine, Hôpital du Sacré-Caeur, 5400 Boul. Gouin Ouest, Montréal, QC, Canada H4J 1C5. f-madore@crhsc.umontreal.ca
D005921:Glomerulonephritis / Q000628:therapy*; D006463:Hemolytic-Uremic Syndrome / Q000628:therapy; D006801:Humans; D010956:Plasmapheresis / Q000009:adverse effects / Q000379:methods*; D011696:Purpura, Thrombocytopenic / Q000628:therapy; D051437:Renal Insufficiency / Q000209:etiology / Q000628:therapy*